Brind.
  1. First patient dosed in Phase 2a trial in Australia for Seaport Therapeutics, a company founded by PureTech Health plc.

PureTech Health plc and Seaport Therapeutics presented clinical data in Munich.

1 report, 1 independent Updated Oct 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

PureTech Health plc and Seaport Therapeutics presented clinical data in Munich.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped